Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Chan

Showing results (401-410 of 449) with videos related to

Pageof 45
Sort By:
NPJ Vaccines|September 9, 2024
Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variantsSneha Vishwanath, George William Carnell, Martina Billmeier, et al.
Inflammatory Bowel Diseases|November 28, 2013
Challenges in designing a national surveillance program for inflammatory bowel disease in the United StatesMillie D Long, Susan Hutfless, Michael D Kappelman, et al.
Neurosurgery|September 23, 2022
Correlation of the Modified Japanese Orthopedic Association With Functional and Quality-of-Life Outcomes After Surgery for Degenerative Cervical Myelopathy: A Quality Outcomes Database StudyTimothy J Yee, Cheerag Upadhyaya, Domagoj Coric, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 6, 2013
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohortTomas Olsson, Anat Achiron, Lars Alfredsson, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
Eclinicalmedicine|January 26, 2026
Association between statin use and risk of incident cancer in healthy older adults: a target trial emulation using data from a multicentre, randomised trial of community-dwelling older adults in Australia and the USAGebiso Roba Debele, Najmeh Davoodian, Mojtaba Lotfaliany, et al.
Lancet (London, England)|November 20, 2018
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trialHisham Mehanna, Max Robinson, Andrew Hartley, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 8, 2015
Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-βMarta F Bustamante, Carlos Morcillo-Suárez, Sunny Malhotra, et al.
Neurology|August 9, 2013
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patientsNicholas Schwab, Tilman Schneider-Hohendorf, Vilmos Posevitz, et al.
Pageof 45

Showing results (401-410 of 449) with videos related to

Sort By:
Pageof 45
NPJ Vaccines|September 9, 2024
Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variantsSneha Vishwanath, George William Carnell, Martina Billmeier, et al.
Inflammatory Bowel Diseases|November 28, 2013
Challenges in designing a national surveillance program for inflammatory bowel disease in the United StatesMillie D Long, Susan Hutfless, Michael D Kappelman, et al.
Neurosurgery|September 23, 2022
Correlation of the Modified Japanese Orthopedic Association With Functional and Quality-of-Life Outcomes After Surgery for Degenerative Cervical Myelopathy: A Quality Outcomes Database StudyTimothy J Yee, Cheerag Upadhyaya, Domagoj Coric, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 6, 2013
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohortTomas Olsson, Anat Achiron, Lars Alfredsson, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
Eclinicalmedicine|January 26, 2026
Association between statin use and risk of incident cancer in healthy older adults: a target trial emulation using data from a multicentre, randomised trial of community-dwelling older adults in Australia and the USAGebiso Roba Debele, Najmeh Davoodian, Mojtaba Lotfaliany, et al.
Lancet (London, England)|November 20, 2018
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trialHisham Mehanna, Max Robinson, Andrew Hartley, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 8, 2015
Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-βMarta F Bustamante, Carlos Morcillo-Suárez, Sunny Malhotra, et al.
Neurology|August 9, 2013
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patientsNicholas Schwab, Tilman Schneider-Hohendorf, Vilmos Posevitz, et al.
Pageof 45